deltatrials
Completed PHASE3 NCT00002855

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate

Sponsor: M.D. Anderson Cancer Center

Conditions Prostate Cancer
Interventions Bicalutamide Conventional Surgery Doxorubicin hydrochloride Estramustine Phosphate Sodium Flutamide Ketoconazole Nilutamide Therapeutic Hydrocortisone Vinblastine
Updated 7 times since 2017 Last updated: Oct 30, 2018 Started: Aug 31, 1996 Primary completion: Jun 30, 2005 Completion: Jun 30, 2005

Listed as NCT00002855, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 1996, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Nov 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Nov 2018 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Aug 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States